Search

News Turoctocog Alfa Pegol with Extended Half-Life in the Treatment of Severe Hemophilia A

GlycoPEGylated recombinant factor VIII (rFVIII) with an extended half-life, turoctocog alfa pegol, has demonstrated prophylactic efficacy in patients with severe hemophilia A aged over 12. This product is administered only once every 4 days. In addition to a comparable reduction in the annual bleed rate to standard FVIII prophylaxis products, it has also shown sufficient efficacy in bleeding treatment and a minimal risk of inhibitory antibody formation.

Source: Hemophilia with Movement 28. 1. 2021

News Heart Failure in the Light of New ESC Guidelines

Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd, at 5 PM.
You can find more information in the invitation attached below.

Source: Heart Failure 27. 10. 2021

News Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy

New molecules in hemophilia therapy have raised many questions, including regarding the significance and need for immune tolerance induction (ITI). Interesting conclusions from the FIT (Future of Immunotolerance Treatment) expert panel discussion on the future of ITI, its form, and indication were published in July 2019.

Source: Hemophilia 18. 3. 2020

News How to Improve Diabetic Adherence?

The dream of every doctor is a conscientious patient who follows the prescribed treatment and reports any potential problems in a timely manner. But where can such a patient be found?

Source: Diabetes 7. 5. 2020

News In decisions about therapeutic strategy in multiple myeloma, patient preferences and concerns also play a crucial role

The perspective on the preferences of patients with multiple myeloma (MM) is very necessary at a time of rapid development of new treatment options. Patient priorities and their perception of treatment can, alongside the assessment of the efficacy or toxicity of a modality, also influence decisions about the therapeutic strategy.

Source: Hematologic Malignancies 10. 2. 2022

News Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients

Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients, with morbid obesity being a notable risk factor for thromboembolism. Various thromboprophylaxis strategies have been studied in morbidly obese patients; a recently published study compared the efficacy and safety of high doses of enoxaparin and unfractionated heparin.

Source: Thromboprophylaxis 28. 1. 2020

News Are All Patients Really Suitable for Thromboprophylaxis Treated This Way?

A study published this year aimed to assess how often the risk of VTE is assessed in routine clinical practice in internally ill patients, what proportion of patients are suitable for thromboprophylaxis, and how many actually receive this treatment.

Source: Thromboprophylaxis 8. 4. 2020

News Therapy Change from Adalimumab to Baricitinib in Patients with Rheumatoid Arthritis

The aim of the presented analysis of data from the RA-BEAM study was to evaluate the clinical response of patients who were switched to baricitinib during the study due to an inadequate response to adalimumab.

Source: Biological Treatment 30. 3. 2020

News Impact of the combination of bevacizumab with erlotinib in patients with NSCLC and EGFR mutation on overall survival and time to disease progression

Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) can delay resistance to chemotherapy in patients with advanced-stage non-small cell lung cancer (NSCLC). The study presented below examined the efficacy and safety of the erlotinib + bevacizumab combination compared to erlotinib monotherapy in these patients.

Source: Oncological Treatment 21. 11. 2022

News Monotherapy with Bimatoprost in Patients with Glaucoma and Ocular Hypertension

Can monotherapy with bimatoprost be sufficiently effective in controlling intraocular pressure in non-responders to previous treatments? This is the question posed by British researchers in the presented study.

Source: Treatment of Glaucoma 4. 5. 2020

News Basic Information on the Spread and Course of COVID-19 Infection in China: What We Know So Far?

Currently, we are experiencing a worldwide outbreak of COVID-19 infection caused by the SARS-CoV-2 virus, with the first cases identified in December 2019 in Wuhan, China. As of March 18, 2020, according to WHO information, the virus has spread to six continents and a total of 179,111 people worldwide were infected with COVID-19, of whom 7,426 have died from the disease. Sharing transparent, valid, and relevant information is one of the cornerstones of the fight to mitigate the impact of this infection. Chinese authors recently published a summary of current knowledge on the epidemiology, clinical manifestations, diagnosis, treatment, and prevention of COVID-19, valid as of March 2, 2020, in the International Journal of Infectious Diseases.

Source: Anti-Infectives 17. 3. 2020

News Luck in Unluckiness: Influence of Anticoagulant Therapy on Severity of Stroke in Atrial Fibrillation

A recent Swiss study evaluated the severity, complications, and outcomes of cerebrovascular accidents (CVAs) in patients with atrial fibrillation considering prior anticoagulant therapy use and its type. This allowed for a comparison between direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs).

Source: Anticoagulant Treatment 25. 4. 2022

News Safety of Tofacitinib in Ulcerative Colitis –⁠ Combined Results of 6 Studies

At the annual meeting of the American Gastroenterological Association (ACG) in October 2023 in Vancouver, Canada, the results of the final safety analysis of tofacitinib in the treatment of ulcerative colitis from a clinical trial program involving 1,157 patients with exposure duration to this therapy of up to 9.2 years were presented.

Source: Intestinal Inflammations 7. 12. 2023

News Sport and Programmed Sports Therapy in Hemophiliacs

Sport and physical activity are increasingly becoming an integrated part of the treatment plan for hemophiliacs. It was not long ago that sports were almost forbidden for these patients. The possibilities for active movement were determined by the availability of effective treatment. It has also become clear that sport is not just sport but to some extent also part of the treatment –⁠ thanks to the care of experienced physiotherapists.

Source: Hemophilia with Movement 2. 9. 2020

News Participation in sports activities, frequency and severity of sports injuries in children with hemophilia

Children with hemophilia used to be discouraged from engaging in sports activities due to the potential increased risk of bleeding. The introduction of prophylaxis into routine practice has improved the possibility for children to participate in various sports activities. A study conducted by Dutch authors evaluated the involvement of boys with hemophilia in sports activities and their potential link with sports injuries and bleeding.

Source: Hemophilia with Movement 28. 3. 2022